Managed Healthcare Executive interviews Lindsay Bealor Greenleaf, Director at ADVI, about biosimilars
***excerpt***
"Biosimilars present an opportunity for cost savings in managed care, but the degree of savings will depend on physician prescribing behavior, biosimilar pricing and finalized guidance from the FDA on interchangeability," explains Lindsay Bealor Greenleaf, director at ADVI, a healthcare consulting firm that advises life science companies and provider organizations.
Managed Healthcare Executive interviews Lindsay Bealor Greenleaf, Director at ADVI, about biosimilars
Wednesday, August 02, 2017
***excerpt***
“Biosimilars present an opportunity for cost savings in managed care, but the degree of savings will depend on physician prescribing behavior, biosimilar pricing and finalized guidance from the FDA on interchangeability,” explains Lindsay Bealor Greenleaf, director at ADVI, a healthcare consulting firm that advises life science companies and provider organizations.
***end excerpt***
***
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.